Background Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast
differentiation, activation, and survival. The fully human monoclonal antibody denosumab (…

Objective Etanercept has been shown to improve the articular and cutaneous manifestations
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect …

Objective To determine the safety and efficacy of etanercept in a multicenter, randomized,
placebo‐controlled, double‐blind trial of adults with moderate to severe active ankylosing …

ContextIn vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not
COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without …

Objective To evaluate the safety and efficacy of adalimumab, a fully human recombinant IgG1
monoclonal antibody that specifically targets human tumor necrosis factor, in patients with …

Objective To assess the efficacy and safety of rilonacept (Interleukin‐1 [IL‐1] Trap), a long‐acting
and potent inhibitor of IL‐1, in patients with cryopyrin‐associated periodic syndromes (…

Objective To evaluate the clinical response, safety, and tolerability of a single intraarticular
injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee. Methods …

Background Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate
the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …